Curemark, LLC - Product Pipeline Review - 2014

Curemark, LLC - Product Pipeline Review - 2014

Regular price $1,500.00 Sale

Published on Jun 10, 2014 - 23 pages

Global Markets Direct's, 'Curemark, LLC - Product Pipeline Review - 2014', provides an overview of the Curemark, LLC's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Curemark, LLC's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides brief overview of Curemark, LLC including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Curemark, LLC's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Curemark, LLC's pipeline products
Reasons to buy
  • Evaluate Curemark, LLC's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Curemark, LLC in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Curemark, LLC's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Curemark, LLC and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Curemark, LLC
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Curemark, LLC and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues


Table of Contents

Table of Contents
Table of Contents
List of Tables
List of Figures
Curemark, LLC Snapshot
Curemark, LLC Overview
Key Information
Key Facts
Curemark, LLC - Research and Development Overview
Key Therapeutic Areas
Curemark, LLC - Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products - Monotherapy
Curemark, LLC - Pipeline Products Glance
Curemark, LLC - Late Stage Pipeline Products
Pre-Registration Products/Combination Treatment Modalities
Phase III Products/Combination Treatment Modalities
Curemark, LLC - Early Stage Pipeline Products
Preclinical Products/Combination Treatment Modalities
Curemark, LLC - Drug Profiles
CM-AT
Product Description
Mechanism of Action
R&D Progress
CM-4612
Product Description
Mechanism of Action
R&D Progress
CM-1212
Product Description
Mechanism of Action
R&D Progress
CM-182
Product Description
Mechanism of Action
R&D Progress
CM-PK
Product Description
Mechanism of Action
R&D Progress
Curemark, LLC - Pipeline Analysis
Curemark, LLC - Pipeline Products by Route of Administration
Curemark, LLC - Pipeline Products by Molecule Type
Curemark, LLC - Recent Pipeline Updates
Curemark, LLC - Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Curemark, LLC, Key Information
Curemark, LLC, Key Facts
Curemark, LLC - Pipeline by Indication, 2014
Curemark, LLC - Pipeline by Stage of Development, 2014
Curemark, LLC - Monotherapy Products in Pipeline, 2014
Curemark, LLC - Pre-Registration, 2014
Curemark, LLC - Phase III, 2014
Curemark, LLC - Preclinical, 2014
Curemark, LLC - Pipeline by Route of Administration, 2014
Curemark, LLC - Pipeline by Molecule Type, 2014
Curemark, LLC - Recent Pipeline Updates, 2014

List of Figures
Curemark, LLC - Pipeline by Top 10 Indication, 2014
Curemark, LLC - Pipeline by Stage of Development, 2014
Curemark, LLC - Monotherapy Products in Pipeline, 2014
Curemark, LLC - Pipeline by Top 10 Molecule Type, 2014

Companies Mentioned:

Curemark, LLC